Northern Trust Corp Sells 49,004 Shares of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)

Northern Trust Corp lowered its position in shares of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) by 10.5% during the second quarter, HoldingsChannel.com reports. The fund owned 419,711 shares of the biopharmaceutical company’s stock after selling 49,004 shares during the quarter. Northern Trust Corp’s holdings in Bellicum Pharmaceuticals were worth $714,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of BLCM. Nikko Asset Management Americas Inc. boosted its position in Bellicum Pharmaceuticals by 98.5% during the second quarter. Nikko Asset Management Americas Inc. now owns 2,105,649 shares of the biopharmaceutical company’s stock valued at $3,580,000 after acquiring an additional 1,044,811 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its position in Bellicum Pharmaceuticals by 98.5% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,105,649 shares of the biopharmaceutical company’s stock valued at $3,580,000 after acquiring an additional 1,044,811 shares during the last quarter. Renaissance Technologies LLC boosted its position in Bellicum Pharmaceuticals by 58.7% during the second quarter. Renaissance Technologies LLC now owns 1,564,959 shares of the biopharmaceutical company’s stock valued at $2,660,000 after acquiring an additional 579,000 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new stake in Bellicum Pharmaceuticals during the second quarter valued at $233,000. 52.21% of the stock is currently owned by institutional investors and hedge funds.

In related news, CEO Richard A. Fair acquired 40,000 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were purchased at an average price of $1.25 per share, for a total transaction of $50,000.00. Following the completion of the acquisition, the chief executive officer now owns 66,561 shares of the company’s stock, valued at $83,201.25. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have bought 68,000 shares of company stock worth $79,640 in the last quarter. Company insiders own 2.64% of the company’s stock.

A number of analysts have commented on BLCM shares. Zacks Investment Research cut shares of Bellicum Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 8th. ValuEngine raised shares of Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st.

Shares of NASDAQ BLCM opened at $0.80 on Friday. The firm’s 50-day moving average price is $1.04 and its 200-day moving average price is $1.90. Bellicum Pharmaceuticals Inc has a 1-year low of $0.78 and a 1-year high of $5.50. The firm has a market capitalization of $37.47 million, a P/E ratio of -0.33 and a beta of 1.52. The company has a current ratio of 2.67, a quick ratio of 2.67 and a debt-to-equity ratio of 1.23.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last announced its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.04). Bellicum Pharmaceuticals had a negative net margin of 4,081.44% and a negative return on equity of 169.33%. The company had revenue of $1.39 million for the quarter, compared to analyst estimates of $0.23 million. Equities research analysts forecast that Bellicum Pharmaceuticals Inc will post -2.12 EPS for the current year.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen.

Featured Story: Why do companies issue stock splits?

Want to see what other hedge funds are holding BLCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bellicum Pharmaceuticals Inc (NASDAQ:BLCM).

Institutional Ownership by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.